Advertisement
Advertisement
BCYC
Bicycle Therapeutics plc - ADR
4.17
USDSponsored
+0.20
+5.04%
Aug 07, 15:59 UTC -4
Closed
After-Market
4.16
-0.01
-0.24%
BCYC Earnings Reports
Positive Surprise Ratio
BCYC beat 13 of 29 last estimates.
45%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$4.17M
/-$0.51
Implied change from Q2 26 (Revenue/ EPS)
+563.41%
/-29.17%
Implied change from Q3 25 (Revenue/ EPS)
-64.44%
/-40.00%
Bicycle Therapeutics plc - ADR earnings per share and revenue
On Jul 30, 2026, BCYC reported earnings of -0.72 USD per share (EPS) for Q2 26, missing the estimate of -0.58 USD, resulting in a -22.64% surprise. Revenue reached 629.00 thousand, compared to an expected 4.31 million, with a -85.39% difference. The market reacted with a +3.89% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.51 USD, with revenue projected to reach 4.17 million USD, implying an decrease of -29.17% EPS, and increase of 563.41% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Bicycle Therapeutics plc - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Bicycle Therapeutics plc - ADR reported EPS of -$0.72, missing estimates by -22.64%, and revenue of $629.00K, -85.39% below expectations.
How did the market react to Bicycle Therapeutics plc - ADR's Q2 2026 earnings?
The stock price moved up 3.89%, changed from $3.86 before the earnings release to $4.01 the day after.
When is Bicycle Therapeutics plc - ADR expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Bicycle Therapeutics plc - ADR's next earnings report?
Based on 7
analysts, Bicycle Therapeutics plc - ADR is expected to report EPS of -$0.51 and revenue of $4.17M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement